Latest news

• Ocrevus surge keeps Roche smiling in Q3

  However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led

• Roche’s Alecensa backed by China’s National Drug Administration

  of that is Swiss drug maker Roche, which today received an approval to market its lung cancer treatment Alecensa in the country. ... Alecensa is now approved in over 57 countries as a first-line treatment for ALK-positive NSCLC.

• Daily Brief: DeepMind and NHS success in AI, Bayer invests in COPD, Alecensa OK in Scotland

  Roche’s Alecensa approved by Scottish Medicines Consortium. Patients in Scotland with untreated, advanced non-small-cell lung cancer (NSCLC) with ALK-positive tumours have a new treatment option available via ... Alecensa is challenging Pfizer’s

• Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

  Strong launches for new medicines Ocrevus, Tecentriq and Alecensa, especially in Germany, partially offset the loss in Europe.

• Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach

  Xalkori is for now keeping one step ahead of rival treatments, such as Novartis’ Zykadia, which gained NICE approval for use in ALK+ patients in January, and Roche’s Alecensa, which